{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-100608","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.517869+00:00","generated_at":"2026-05-17T03:19:50.480994+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"VIRAGE Phase 2b trial meets primary OS endpoint; VCN-01+SoC mOS 10.8 vs 8.6 months","bullets":["VCN-01 + gem/nab-paclitaxel met primary OS endpoint in FAS: median 10.8 vs 8.6 months, HR 0.57 (p=0.034).","PFS improved: 7.0 vs 4.6 months (HR 0.55, p=0.012) and duration of response doubled (11.2 vs 5.4 months).","Patients receiving 2 VCN-01 doses had greater OS benefit: median 14.8 vs 11.6 months (HR 0.44).","VCN-01 was safe and well tolerated; related SAEs were transient and resolved.","Data support further evaluation in larger blinded trial with additional VCN-01 doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-100608","json":"https://secwatch.observer/filing/0001104659-25-100608.json","markdown":"https://secwatch.observer/filing/0001104659-25-100608.md","text":"https://secwatch.observer/filing/0001104659-25-100608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925100608/0001104659-25-100608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925100608/tm2529071d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:19:50.480994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}